Union européenne - français - EMA (European Medicines Agency)

sanofi b.v. - thyrotropine alfa - néoplasmes thyroïdiens - lobe antérieur de l'hypophyse hormones et analogues, l'hypophyse et les hormones hypothalamiques et analogues - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - thyrotropinum alfa - poudre versez solution injectable - praeparatio cryodesiccata: thyrotropinum alfa 0.9 mg, mannitolum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, pro vitro corresp. natrium 1.19 mg. - cancer de la thyroïde - biotechnologika

Canada - français - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - thyrotropine alfa - poudre pour solution - 0.9mg - thyrotropine alfa 0.9mg - thyroid function